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Summary: Purpose: To quantify the risks of intrauterine an­
tiepileptic drug (AED) exposure in monotherapy and poly- 
therapy.
Methods: Data from five prospective European studies total­
ing 1,379 children were pooled and reanalyzed. Data were 
available for 1,221 children exposed to AED during pregnancy 
and for 158 children of unexposed control pregnancies.
Results: Overall, when comparing a subgroup of 192 children 
exposed to AED with 158 children of matched nonepileptic 
controls, there was an increased risk of major congenital mal­
formations (MCA) in children exposed to AED during gesta­
tion [relative risk (RR) 2.3; 95% confidence interval (Cl): 1.2-
4.7]. A significant increase in risk was found for children ex­
posed to valproate (VPA) (RR 4.9; 95% Cl: 1.6-15,0) or 
carbamazepine (CBZ) (RR 4.9; 95% Cl: 1,3-18.0) in mono­
therapy. When comparing different AED regimens during all 
1,221 pregnancies, risks of MCA were significantly increased
for the combination of phenobarbital (PB) and ethosuximide 
(RR 9.8; 95% Cl: 1.4-67,3) and the combination of phenytoin, 
PB, CBZ, and VPA (RR 11.0; 95% Cl: 2.1-57.6). Offspring of 
mothers using >1,000 mg VP A/day were at a significantly in­
creased risk of MCA, especially neural tube defects, compared 
to offspring exposed ^600  mg VP A/day (RR 6.8; 95% Cl:
1.4-32.7). No difference in risk of MCA was found between 
the offspring exposed to 601-1,000 mg/day and ^600 mg/day.
Conclusions: This reanalysis shows that VPA is consistently 
associated with an increased risk of MCA in babies born to 
mothers with epilepsy. Significant associations were also ob­
served with CBZ. Larger prospective population-based studies 
are needed to evaluate the risks of many other less frequently 
prescribed treatment regimens, including newly marketed 
AEDs. Key Words: Antiepileptic drugs—Major congenital 
malformations—Pregnancy—Epileptic offspring.
Maternal use of antiepileptic drugs (AEDs) during 
pregnancy has been associated with an increased risk of 
major congenital abnormalities (MCA) in the fetus. Yet 
in many women planning a pregnancy antiepileptic drugs 
cannot be discontinued because of the risk of seizures 
during pregnancy, which can be harmful to both mother 
and child (1-3). Furthermore, acute discontinuation dur­
ing early pregnancy is also not recommended because of 
the risk of increased numbers of seizures and status epi-
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lepticus (4—6). Many children of women with epilepsy 
are therefore at a two- to threefold increased risk of 
congenital malformations as compared with the general 
population (7-14) and an important clinical issue is how 
to treat women with epilepsy during pregnancy (15-18).
Many questions concerning risks associated with the 
specific AEDs are unanswered. In the studies conducted 
to date, no specific drug regimen has consistently shown 
a lower risk than any other, suggesting that AED therapy 
is implicitly related to an increased risk of congenital 
malformations. However, in most of these studies, the 
number of pregnancies was relatively small (19-23), 
which limits the possibilities for detecting potential
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dose-response relationships. Furthermore, studies may 
differ in regard to both definitions and procedures. In a 
collaborative analysis, these factors can be taken into 
account by increasing the number of subjects, application 
of standardized definitions, and evaluation of effects that 
are consistent across studies.
Therefore, to quantify the specific risks of AEDs in 
m onotherapy and polytherapy, we reanalyzed data 
pooled from five prospective European studies. The pre­
sent study focuses on pregnancies in women with epi­
lepsy treated with AEDs* The first aim was to assess the 
risk of MCA of children exposed in utero to AEDs dur­
ing pregnancy as compared with the risk of children not 
exposed to AEDs. The second aim was to quantify risks 
of MCA associated with specific AED regimens.
METHODS
For the present study, raw data from five studies were 
pooled. These studies included were prospective studies 
conducted in Europe from 1971 to 1990. The studies 
were selected on the basis of their prospective design and 
before knowing the outcome to minimize selection bias. 
One study was conducted in Helsinki, Finland; 2 studies 
were conducted in Germany, 1 in Berlin (former West
Berlin) and 1 in Magdeburg; and 2 were conducted in 
The Netherlands, 1 in the South West Netherlands, in­
cluding, the municipality of Rotterdam, and 1 in the out­
patient clinics of the Dutch Special Centres for Epilepsy. 
Included in the studies were 896 women with epilepsy 
treated with AEDs and 1,221 children born to these sub­
jects, and 158 children born to nonepileptic control sub­
jects (Table 1). Of the AED-treated women, 326 (36%) 
had generalized epilepsy, 484 (54%) had localization- 
related epilepsy, and 28 (3%) had unclassified epilepsy; 
in 58 (1%) women, the type of epilepsy was unknown. 
The assessment of seizures during pregnancy, especially 
in the first trimester, was incomplete and varied among 
study groups with respect to assessment procedures and 
definition. Therefore, adequate and comparable data on 
seizure frequency were not available for reanalysis.
Individual studies
During the 1981 workshop in Berlin on Epilepsy, 
Pregnancy, and the Child, participating groups compared 
their prospective study designs and concluded that the 
different studies were adequately comparable and there­
fore suitable for a collaborative analysis, once the indi­
vidual studies had been published. All were designed as 
prospective studies of the reproductive outcome of preg­
TABLE 1. Details of individual studies
Germany
Finland,
Netherlands
Parameter Berlin Magdeburg Helsinki Rotterdam Epilepsy Institutes
Years of study 1979-1990 1979-1987 1976-1979 1985-1990 1972-1990
No. of AED-exposed 150 42 106 305 618
pregnancies
No. of nonepileptic 116 42 -------- - ---------- -----------
pregnancies
Matching criteria Maternal age, parity, 
social class, 
smoking, abortions
Maternal age* parity, 
social class, 
smoking, abortions, 
sex, obstetric clinic
Time of matching During pregnancy After delivery ---------- ----------
Exclusion criteria Immature delivery Stillbirth and 
neonatal deaths, 
nonepileptic 
controls with 
family history of 
epilepsy
Immature delivery
Endpoints Major and minor Major and minor Major and minor Major congenital Major congenital
congenital congenital congenital malformations malformations
malformations and malformations and malformations and and body and body
body
measurements
body
measurements
body
measurements
measurements measurements
Time of examination Birth, 1 and 4 yr Birth, 1.5 and 5 yr Birth, 1.5 and 5.5 yr 0-3 mo 0-3 mo
Examination by Pediatrician Pediatrician Pediatric neurologist Gynecologist or 
pediatrician
Gynecologist or 
pediatrician
Diagnosis of Neurologist Neurologist Neurologist Neurologist Neurologist
epilepsy by
No. of mothers 123 32 97 261 411
exposed to AEDs
No. of mothers 116 42 ----------- ----------- -----------
nonepileptic
Exposure information Prospective Prospective Prospective Prospective Prospective
AED, antiepileptic drug.
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nancies of women with epilepsy. The studies recruited all 
consecutive pregnant women with epilepsy. These stud­
ies conducted in Berlin and Magdeburg also included 
nonepileptic control pregnancies. During the 1985 Inter­
national Epilepsy Symposium held in Hamburg, Ger­
many, a collaborative analysis of the data from these 
centers was agreed upon and a grant application was 
approved by the International League Against Epilepsy 
and forwarded to the Klingenstein foundation. The com­
parability of case ascertainment and the assessment of 
MCA in the individual studies were evaluated in visits to 
the study centers and discussions of the individual pro­
tocols. The study design, in particular the selection of the 
exposed and nonexposed pregnancies used in this analy­
sis, is described individually for each study herein. The 
studies are ordered alphabetically by city and country.
Berlin, Germany
The Berlin study was conducted between 1979 and 
1990 (24). The study comprised 123 mothers with epi­
lepsy. Included were 150 AED-exposed pregnancies 
(Table 1 ). Only patients whose epilepsy diagnosis was 
confirmed by a neurologist and in whom the first seizure 
occurred before pregnancy were included. Of the cohort, 
80% were ascertained through 12  obstetric clinics in the 
area of Berlin and 20% was ascertained through the neu­
rology department at the former University Hospital 
Charlottenburg. Control pregnancies (n =  116) were se­
lected through the obstetric clinics, matched for maternal 
age at delivery, parity, social class, smoking habits, and 
previous abortions. Patients and controls were recruited 
during pregnancy before fetal outcome was known. For 
each pregnancy, data on maternal epilepsy and AED 
therapy, family history, obstetric history, and smoking, 
alcohol, and drug abuse were collected. Stillbirths and 
neonatal deaths were included. At birth and at 1 and 4 
years, children underwent physical examination by a pe­
diatrician according to a standardized protocol. The end­
points for examination were major and minor malfor­
mations, including body measurements, occurrence of 
neural tube defects, cleft lip and palate, skeletal malfor­
mations, abdominal defects, genitourinary defects, car­
diac defects, and dysmorphic features.
Helsinki, Finland
The Helsinki study was conducted based on ascertain­
ment of pregnancies between 1976 and 1979 (25) and 
comprised 97 mothers with epilepsy. Included were 106 
AED-exposed pregnancies (Table 1). Only patients in 
whom the epilepsy diagnosis was confirmed by a neu­
rologist and in whom the first seizure occurred before 
pregnancy were included. Subjects were recruited during 
weeks 7-24 of pregnancy; all maternity units were asked 
to refer patients with epilepsy for the study to the Hel­
sinki University City Hospital. Patients with premature 
deliveries (pregnancy duration 16-24 weeks) were ex­
cluded, but stillbirths/neonatal deaths were not. Data 
from control pregnancies were not available for this re­
analysis. For each pregnancy, data on maternal epilepsy 
and AED treatment, family history, obstetric history, and 
smoking habits were collected. At birth and at 1.5 and
5.5 years of age, each child was examined by a pediatric 
neurologist according to a standardized protocol (26). 
The endpoints for examination were major and minor 
malformation, including body measurements, occurrence 
of neural tube defects, cleft lip and palate, skeletal mal­
formations, abdominal defects, genitourinary defects, 
cardiac defects, and dysmorphic features.
Magdeburg, Germany
Pregnancies were ascertained between 1979 and 1987 
according to a protocol similar to that of the Berlin study 
(27,28). There were 32 mothers with epilepsy and 42 
AED-exposed pregnancies (Table 1). The diagnosis of 
epilepsy was always confirmed by a neurologist. In all 
but 4 patients, the first seizure occurred before preg­
nancy. Patients were referred to the coordinating pediat­
ric neurologist by two obstetric departments. The next 
delivery after birth of the exposed infant was selected as 
a control pregnancy (n =  42). The matching criteria 
were sex, obstetric clinic, maternal age at delivery, par­
ity, social class, smoking habits, and previous abortions. 
Women with a positive family history of epilepsy were 
excluded as controls. Subjects were recruited during 
pregnancy. Patients and controls with stillbirths and neo­
natal deaths were excluded, since the primary endpoint 
of the study was postnatal development. Data on mater­
nal epilepsy and AED therapy, family history, obstetric 
history, and smoking, alcohol, and drug abuse were col­
lected. At birth and at 1.5 and 5 years, physical exami­
nation was performed by a pediatrician according to a 
standardized protocol. The endpoints for examination 
were major and minor malformations, including body 
measurements, occurrence of neural tube defects, cleft 
lip and palate, skeletal malformations, abdominal de­
fects, genitourinary defects, cardiac defects, and dysmor­
phic features.
Rotterdam, The Netherlands
The Rotterdam study was conducted from 1985 to 
1990 and comprised 261 women with epilepsy (23,29- 
31) consecutively referred to the outpatient clinic for 
prenatal diagnosis of the University Hospital Rotterdam, 
because of epilepsy with AED (or without AED) treat­
ment. Subjects were recruited before month 4 of preg­
nancy. Only patients whose epilepsy diagnosis was con­
firmed by a neurologist were included. Data were avail­
able on 305 AED-exposed pregnancies (Table 1). Either 
amniocentesis or structural ultrasound (and in most pa­
tients, both) was performed. Some pregnancies were in­
terrupted because o f MCA discovered during prenatal 
testing. These pregnancies were included in the study.
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No control pregnancies are available. Data on maternal 
epilepsy and AED therapy, family history, obstetric his­
tory, and smoking, alcohol, and drug abuse were col­
lected. Pregnancies ending in stillbirth or neonatal death 
were included. Neonatal examination was performed by 
a gynecologist or pediatrician, and defects observed in 
the first 3 months of life were included. The main end­
points were MCA, including body measurements, occur­
rence of neural tube defects, cleft lip and palate, skeletal 
malformations, abdominal defects, genitourinary defects, 
cardiac defects, and dysmorphic features.
Institutes of Epilepsy, The Netherlands
The Institutes of Epilepsy cohort consisted of 411 
women with epilepsy derived from 1 of 14 outpatient 
clinics of the Special Centres for Epilepsy in The Neth­
erlands (Instituut voor Epilepsie bestrijding Heemstede, 
Kempenhaeghe Heeze, and Dr. Hans B erger-kliniek Br­
eda) from period 1972 to 1990. In these centers, ~ 7% of 
all patients with epilepsy in the Netherlands are treated. 
Included were 618 consecutive AED-exposed pregnan­
cies (Table 1). The entire cohort was subdivided into 
three groups (A, B, and C). The first study (cohort A) 
was conducted between 1972 and 1979 and comprised 
151 AED-exposed pregnancies (32-34). The second 
study (cohort B) was conducted between 1980 and 1985 
and comprises 172 AED-exposed pregnancies (11). The 
remaining pregnancies (cohort C) were collected be­
tween 1985 and 1990 and consist of 295 AED-exposed 
pregnancies (not previously published). Diagnosis of epi­
lepsy was confirmed by a neurologist. No control preg­
nancies are available. Subjects were recruited during or 
before pregnancy, and AED exposure was monitored 
during pregnancy. All abortions, premature deliveries, 
and stillbirths are included. Data on maternal epilepsy 
and AED treatment, family history, obstetric history, and 
smoking, alcohol, and drug abuse were collected by the 
attending neurologist, and forms were completed at the 
first visit to the outpatient clinic after delivery (usually 
3-5 months after delivery). The neonatal examination 
was performed by a gynecologist or pediatrician, and 
MCA discovered within 3 months after birth were used 
in the analysis. The main endpoints were MCA, includ­
ing body measurements, occurrence of neural tube de­
fects, cleft lip and palate, skeletal malformations, ab­
dominal defects, genitourinary defects, cardiac defects, 
and dysmorphic features.
Assessment of malformations
For this analysis, we defined M CA as an abnormality 
of an essential embryonal structure, present at birth or 
discovered during the first 3 months of life and requiring 
major intervention before the first year of life. Examples 
of MCA according to this definition are: neural tube 
defects, congenital heart defects, hypospadias, cleft lip 
and palate, pre- and/or postaxial polydactyly, club foot,
congenital hip dysplasia requiring plaster therapy, and 
inguinal hernia, requiring operation.
Data analysis
Raw data from the participating sites were pooled and 
reanalyzed for the reanalysis. The data were analyzed in 
two ways. First, the occurrence of MCA associated with 
maternal epilepsy and AED exposure were compared 
with the occurrence of MCA in control pregnancies. Be­
cause the latter were available only for the Berlin and 
Magdeburg studies, this analysis was limited to those 
two studies. We performed multiple logistic regression to 
estimate the relative risk (RR), using all nonepileptic 
controls as a reference and adjusting for the matching 
variables by including them in the regression model. RR 
are presented with a 95% confidence interval (95% Cl), 
which will exclude the value 1 in case of statistical sig­
nificance (p < 0.05).
Second, risks associated with specific AED regimens 
were compared between pregnancies exposed to differ­
ent regimens. RR were used to quantify the strength of 
the association and are presented with 95% CI. Multiple 
logistic regression analysis was used to adjust for puta­
tive confounding variables such as maternal age, parity, 
social class, sex of the child, study site, type of epilepsy, 
and dose of medication. If AEDs were used in sufficient 
numbers, we tested for the presence of a dose-response 
relationship, with cutoff points based on tertiles. For this 
analysis, no data from the Helsinki study were available.
RESULTS
There were differences among the five studies with 
regard to age at birth, parity, social class, and sex of the 
child (Table 2). Pregnancies occurred at younger age in 
Germany and at older age in the Rotterdam study. There 
were more nulliparous women in the Dutch Epilepsy 
Institutes and in Germany. There were fewer skilled 
manual laborers in the Rotterdam study.
The distribution of the different AED regimens for 
each center, with the percentages of MCA for each regi­
men, is shown in Table 3. Prescription regimens differed 
between the centers. In the Rotterdam study and the 
Dutch Institutes of Epilepsy study, there was a tendency 
toward more frequent prescription of carbamazepine 
(CBZ), valproate (VPA), and combination therapies, 
whereas phenytoin (PHT) and phenobarbital (PB) were 
prescribed less frequently than in the other studies. In 
Berlin and Magdeburg, PHT and primidone (PRM) were 
prescribed more often than CBZ and VPA. In Helsinki, 
the most frequently prescribed drugs were PHT and 
CBZ. The risk of MCA also differed significantly among 
centers. Significantly more MCA were detected in Berlin 
(16%) and Magdeburg (14%) than in the other centers 
(Table 3).
We first compared the risks of MCA in AED-exposed
Epilepsia, Vol, 38, No. 9, 1997
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TABLE 2. Details of study population
Parameter
Germany: Berlin 
and Magdeburg“
Finland,
Helsinki
Netherlands
AED-exposed
Nonepileptic
controls Rotterdam
Epilepsy
Institutes
No. of pregnancies 192 158 106 305 618
Age (yr), n (%)
<19 18(9) 11(7) 4(4) 8 (2) 5(1)
20-24 72 (38) 64(41) 28 (26) 60 (20) 137 (22)
25-29 68 (35) 51 (32) 45 (42) 103 (34) 297 (48)
30-34 28 (15) 25(16) 20(19) 97 (32) 146 (24)
35+ 6(3) 7(4) 9(9) 37 (12) 33 (5)
Parity, n (%)
0 82 (42) 72 (46) ---------- 121 (40) 311 (50)
1 57 (30) 59 (37) ---------- 108 (35) 210 (34)
2+ 52 (27) 26(16) ---------- 74 (24) 97(16)
Unknown 1 (1) K D ---------- 2 (1) ----------
Social class, n (%)
Academic degree 3(2) 3(2) 15(14) 17 (6) ----------
White collar 41 (21) 29(19) 33 (31) 102 (33) ----------
Skilled manual 104 (54) 106 (67) 45 (43) 88 (29) ----------
Unskilled manual 39 (20) 18(11) 13(12) 37(12) ----------
Unknown 5(3) 2 (1) 61 (20) ----------
Sex of child, n {%)
M 103 (54) 84 (53) 52 (49) 148 (48) 299 (48)
F 89 (46) 74 (47) 54 (51) 156 (51) 279 (45)
Unknown7' ---------- ----------- ---------- 1 (0.3) 40 (7)
AED, antiepileptic drug,
"In  all, 150 exposed and 116 nonexposed pregnancies were derived from Berlin; 42 exposed and 42 non­
exposed pregnancies were derived from Magdeburg, 
b Miscarriage; no sex determination.
pregnancies with those in matched control pregnancies, 
using the data from the studies from Berlin and Magde­
burg (Table 4). Overall, we noted a significantly in­
creased risk of MCA in children of mothers with epi­
lepsy treated with AEDs during pregnancy as compared 
with children of healthy controls (RR 2.3, 95% Cl 1.2-
4.7). Moreover, the risk of MCA was significantly in­
creased in children of women treated with CBZ (RR 4.9, 
95% Cl 1.3-18.0) and in children exposed to VPA (RR 
4.9, 95% Cl 1.6-15.0). Most other therapies also showed 
an increased RR, although it was not significant. How­
ever, the number of women treated with these AEDs was 
very small, in particular the number treated with PB and 
with most polytherapy regimens. When adjustment was 
made for maternal age, sex of the child, social class or 
parity of the mother, or type of maternal epilepsy in our 
multiple logistic regression analysis, none of the RR 
shown in Table 4 changed materially (data not shown in 
Table 4).
Second, using the data of all centers, we compared the 
risks of MCA between the different drug regimens. We 
first calculated the risk of MCA in the different AED 
regimens, using all AED-exposed pregnancies pooled 
from all five centers (Table 5). The AED (monotherapy) 
associated with the lowest percentage of MCA (i.e., 
PHT) was used as a reference for comparisons with other 
AED regimens. In the crude overall analysis, there were 
no significant differences in RR of MCA between the
different monotherapy AED regimens. In children of 
mothers treated with VPA monotherapy, however, the 
absolute risk of neural tube defects was 3.8% as com­
pared with 1.0% in those receiving CBZ monotherapy 
and 0% in those receiving other monotherapy regimens. 
For the polytherapies studied, only the combinations of 
PB and ethosuximide (ESM) (RR 9.8, 95% Cl 1.4-67.3; 
n =  5) and PHT, PB, CBZ, and VPA (RR 11.0, 95% Cl
2.1-57.6; n =  7) were shown to pose a significantly in­
creased risk of MCA as compared with PHT mono­
therapy, but very few women received these drug com­
binations. When adjustment was made for confounders 
such as type of epilepsy (Table 5), study center, and 
socioeconomic status, only study center influenced the 
effects of the drug regimens (data not shown in Table 5). 
When adjustment was m ade for study center, the risks of 
MCA for the offspring o f women treated with VPA (RR 
3.7, 95% Cl 1.2-11.8), CBZ (RR 2.8, 95% Cl 1.1-7.3), 
and PB (RR 4.2, 95% C l 1.0-18.6) monotherapy were 
significantly increased. An increased risk of MCA in 
offspring of women treated with VPA was evident in all 
but the Helsinki study, in which VPA was not prescribed 
in monotherapy. For the other AED regimens, there was 
no evidence of confounding by study center. We did not 
find significant evidence o f an association between any 
type of epilepsy and the risk of MCA in the offspring.
Finally, we evaluated the possibility of a dose- 
dependent association (Fig. 1). Due to the small catego­
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TABLE 3. Drug regimens and occurrence o f MCA in AED-exposed pregnancies in different study centersa
AED
Germany
Finland,
Helsinki
Netherlands
Total, n (%)Berlin Magdeburg Rotterdam
Epilepsy
Institutes
CBZ 3/10 (30) 1/4 (25) 2/18(11) 5/115(4) 11/133 (8) 22/280 (8)
ESM 1/2 (50) ---------- ---------- 0/2 (0) 0/9 (0) 1/13(8)
PB 0/5 (0) 1/1 (100) ---------- 3/18(17) 1/24 (4) 5/48 (10)
PHT 4/28 (14) 1/5 (20) 4/46 (9) 0/29 (0) 0/33 (0) 9/141 (6)
PRM 2/27 ( 10) 1/ 12(8) 0/1 (0) 1/3 (33) 4/43 (9)
VPA 4/16 (25) 2/5 (40) ---------- 7/64(11) 3/99 (3) 16/184 (9)
CBZ + CZP 0/2 (0) ---------- ---------- 2/7 (29) 0/2 (0) 2/11 (18)
CBZ + VPA ----------- ---------- 1/1 (100) 2/13(15) 6/65 (9) 9/79(11)
PHT + CBZ 1/2 (50) ---------- 1/9(11) 0/6 (0) 2/27 (7) 4/44 (9)
PHT + PB 2/15(13) ---------- 2/10 (20) 1/7(14) 0/8 (0) 5/40(13)
PHT + VPA 1/2 (50) 0/1 (0) 0/5 (0) 0/2 (0) 1/8 (13) 2/18(11)
PB + CBZ ----------- ---------- 0/1 (0) 0/ 10(0) 1/16 (6) 1/27 (4)
PB + ESM 1/3 (33) ---------- ---------- ----------- 1/2 (50) 2/5 (40)
PB + VPA 1/2 (50) ---------- ---------- 0/5 (0) 2/9 (22) 3/16(19)
PRM + VPA 1/8(13) 0/5 (0) ---------- ----------- ----------- 1/13(8)
VPA + CZP ----------- ----------- ---------- 0/3 (0) 1/3 (33) 1/6(17)
VPA + ESM 1/2 (50) ----------- ---------- 0/3 (0) 2/34 (6) 3/39 (8)
CBZ + VPA + CZP ----------- ----------- ---------- 0/1 (0) 1/4 (25) 1/5 (20)
PHT + PB + CBZ +VPA ----------- ---------- ----------- 3/7 (43) 3/7 (43)
Others 3/26 ( 12) 0/9 (0) 0/15 (0) 2/20 (10) 8/132 (6) 13/202 (6)
Total 25/150(17) 6/42 (14) 10/106 (9) 22/305 (7) 46/618 (7) 108/1,221 (9)
MCA, major congenital abnormalities; AED, antiepileptic drug; CBZ, carbamazepine; ESM, ethosuximide; PB, phénobarbital; PHT, phenytoin; 
PRM, primidone; VPA, valproate; CZP, clonazepam.
" Numbers are malformed/total exposed.
ries, we did not adjust these analyses for study center, 
maternal age, sex of the child, social class, parity of the 
mother, or maternal epilepsy. Among women treated 
with VPA offspring of women receiving VPA >1,000 
mg/day had a significant increase in risk of MCA as 
compared with those of women receiving <600 mg/day 
(RR 6.8, 95% Cl 1.4-32.7). The MCA detected in the 
offspring of women receiving VPA 5*1,000 mg/day were 
spina bifida with or w ithout hydrocephalus (n =  5 ; 
28%); ventricular septal defect (n =  1 , 6%); tetralogy of 
Fallot (n =  I, 6%); atrial septal defect (n =  1, 6%); cra- 
niosynostosis (n =  1 , 6%); a combination of meningo­
myelocele, microcephaly, and inguinal hernia (n =  1 , 
6%); and a combination of aplasia of the first rib and 
hypersegmentation of the manubrium sterni (n =  1 , 
6%). PB monotherapy also showed a trend for increased 
risk of M CA with increasing dose, but the differences 
were not significant. Malformations occurring twice or 
more are summarized in Tables 6 and 7.
DISCUSSION
Our findings show an overall increased risk of MCA 
in children of mothers with epilepsy treated with AEDs 
during pregnancy as compared with children of healthy 
controls. The most pronounced increase in risk was that 
for children exposed in utero to VPA or CBZ mono­
therapy. Comparison o f different AED regimens re­
ceived during pregnancy showed that risk of MCA was 
significantly increased for the rare combination of PB
and ESM and the combination of PHT, PB, CBZ, and 
VPA. In an analysis adjusted for study center, this risk 
was also significantly increased for CBZ, PB, and VPA 
in monotherapy. The risk associated with VPA mono­
therapy appeared to be dose dependent. The offspring of 
mothers treated with >1,000 mg/day VPA are at in­
creased risk, in particular of neural tube defects. The risk 
associated with PB also appeared to be dose dependent.
Because our findings are based on nonrandomized 
studies, biases may have occurred. In none of the studies 
pooled were pediatricians or other investigators assess­
ing the presence of MCA blinded to the exposure status 
of the offspring. Furthermore, in this reanalysis, the data 
were pooled from studies that differed considerably in
TABLE 4. RR of MCA: Comparison of AED-exposed and
nonepileptic controlsa
Exposures
Pregnancies, 
n (%)* RR 95% Cl
Nonepileptic controls 12/158(8) 1.0 Reference
CBZ 4/14(29) 4.9 1.3-18.0
PB 1/6(17) 2.4 0.3-23.0
PHT 5/33(15) 2.2 0.7-6.7
PRM 3/39 (8) 1.0 0.3-3 .8
VPA 6/21 (29) 4.9 1.6-15.0
PHT + PB 2/15 (13) 1.8 0.4-9.4
PRM + VPA 1/13 (8) 1.0 0.1- 8.6
Others 8/51 (16) 2.1 0.8-5.4
RR, relative risk; Cl, confidence interval; other abbreviations as in 
Table 3.
" Data available only in Berlin and Magdeburg studies. 
h Numbers are malformations/total exposed.
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FIG. 1. Risk of major congenital malformations posed by increasing dose of the antiepiieptic drug (AED) regimen in monotherapy (cutoff 
points at 33.3 and 66.6%). Above the columns, the upper limit for the 95% confidence interval is shown. Included are all AED regimens 
used ¡n ^30 pregnancies.
TABLE 5. All centers: RR of MCA, comparison of different AED regimens
Exposures"
n, all 
centers (%)
RR
(crude) 95% Cl
RR
(adjusted'') 95% Cl
n
(first pregnancies)
RR
(first pregnancies) 95% Cl
PHT 9/141 (6) 1.0 Reference 1.0 Reference 8/118 1.0 Reference
CBZC 22/280 (8) 1.3 0.6- 2.8 1.2 0.5-2.7 17/210 1.2 0.5-2.9
ESM 1/13 (8) 1.2 0.1-10.7 0.6 0 . 1- 6.8 0/9 ----------- ----------
P B ' ' 5/48 (10) 1.7 0.5-5.4 1.9 0.5-6.9 5/37 2.2 0.7-7.1
PRM 4/43 (9) 1.5 0.4-5.2 1.0 0.3-4.0 4/32 2.0 0.6-7.1
VPA" 16/184 (9) 1.4 0,6-3.3 1.5 0.6-4.0 10/121 1.2 0.5-3.3
CBZ + CZP 2/11 (18) 3.3 0.6-17.6 3.6 0,6-19.7 1/5 3.4 0.3-35.3
VPA + CBZ 9/79(11) 1.9 0.7-5.0 1.9 0.7-5.0 5/48 1.6 0.5-5.2
PHT + CBZ 4/44 (9) 1.5 0.4-5.1 1.5 0.4-5.2 4/34 1.8 0.5-6.6
PHT + PB 5/40(13) 2.1 0.7-6.7 2.0 0.6-6.5 5/34 2.4 0.7-7.9
PHT + VPA 2/18(11) 1.8 0.4-9.4 1.6 0.3-8.4 1/14 1.1 0.1-9.3
PB + CBZ 1/27 (4) 0.6 0.1-4.7 0.5 0.1-3.9 1/19 0.8 0.1- 6,6
PB + ESM 2/5 (40) 9.8 1.4-67.3 7.5 1.0-56.0 1/3 6.9 0.6-86.4
PB + VPA 3/16(19) 3.4 0.8-14.2 2.4 0.5-12.2 3/13 4.1 0.9-18.3
PRM + VPA 1/13 (8) 1.2 0.1-10.7 0.8 0.1-7.4 1/9 1.7 0.2-15.8
VPA + CZP 1/6 (17) 2.9 0.3-28.4 2.5 0.2-25.2 1/6 2.8 0.3-27.1
VPA + ESM 3/39 (8) 1.2 0.3-4.8 0.6 0.1-3.2 3/27 1.7 0.4-7.0
CBZ + VPA + CZP 1/5 (20) 3.7 0.4-37.0 3.7 0.4-37.6 1/2 13.8 0.8-248.0
PHT + PB + CBZ + VPA 3/7 (43) 1 1 . 0 2.1-57.6 13.8 2.5-76.9 2/6 6.9 1.1-44.2
O ther/ 13/202 (6) 1.0 0.4-2.4 0.9 0.4—2.3 13/149 1.3 0.5-2.2
Abbreviations as in Tables 3 and 4.
" RR calculation after adjustment for center was limited by too small numbers, except for CBZ, PB, and VPA. 
b Adjusted for type of epilepsy. 
c RR for CBZ adjusted for center: 2.8 (1.1-7.3).
^RR for PB adjusted for center: 4.2 (1.0-18.6). 
tfRR for VPA adjusted for center: 3.7 (1.2-11.8)’ 
f  All regimens consisting of four pregnancies or fewer.
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TABLE 6. M C A occurring two o r m ore times w ith use o f  m onotherapy (n 2* 20)
ANY
E. B. SAMREN ET AL.
MCA CBZ VPA PHT PB PRM OTHERS (> 2)
Total exposures 280 184 141 48 43 17 713
Inguinal hernia 4 2a 1 ----------- 3 1 11
Spina bifida aperta
3*± hydrocephalus T -----------
J
---------- -----------
8Congenital heart defect ----------- 2 3C 3d -----------
Cleft lip ± palate 3*j* ----------- l c 2 1 ----------- 7
Pre-/postaxial polydactyly y
*
2s 2 ----------- 6
Hypospadias 3 c M 1 1 ----------- ---------- ----------- 5
Clubfoot 2 1 ----------- ----------- ----------- 3
Preauricular ear skintag 1' ----------- 1 ---------- ---------- 1-' 3
Hipluxation 2 ----------- ----------- ---------- ----------- 2
Microcephaly
2V
la 1 ---------- ---------- 2
Ptosis ----------- ----------- ----------- ----------- 2
Others 2k 2’ r ----------- ---------- 1“ 6
MCA, major congenital malformations.
" One case with meningomyelocele» inguinal hernia, and microcephaly.
b One case with palpable defect in sacral spinal arches at birth confirmed radiographically, with normal 
overlying skin.
c One case with congenital heart defect and cleft lip + palate.
rfOne case with congenital heart defect, radius aplasia, and hemivertebrae 1, 3, and 5.
47 One case with cleft lip, hypospadia, and hydrocephalus. 
f  One case with esophageal atresia and preaxial polydactyly. 
s One case with triphalangeal thumb and hemimelia. 
h One case with hypospadia and ptosis.
' One case with preauricular ear skin tag and ptosis, 
j One case with preauricular fistula.
* One case each; hypertrophic pylorus stenosis; asymmetric crying face.
1 One case each: craniosynostosis; aplasia of first rib and hypersegmentation manubrium sterni.
One case with congenital megacolon. 
n One case with chylothorax and persistent fetal circulation,
methods used, including diagnosis and ascertainment of elusion of stillbirths and neonatal deaths in the Magde- 
patients. For the reanalysis, we obtained the raw data burg study. That study was relatively small (n =  42), 
from the individual centers and standardized the criteria and the effect of the exclusion of stillbirths and neonatal 
for MCA. However, we could not adjust for the nonin- deaths on the risk estimates is therefore probably limited.
TABLE 7. M C A  occurring two or m ore tim es with use o f  po ly  therapy (n ^  20)
MCA CBZ ± VPA PHT + CBZ PHT + PB VPA +ESM PB + CBZ Others
Any
(> 2)
Total exposures 79 44 40 39 27 287 512
Inguinal hernia 2 ----------- 1 1 ---------- 3 7
Congenital heart defect ----------- \ n ----------- ---------- 5 6
Cleft lip ± palate I ----------- ----------- ----------- ---------- 5 6
Hypospadia 2 1° 2b ----------- ---------- 1 6
Clubfoot ---------- ----------- ----------- 1 l c 3r/ 5
Hip luxation
Spina bifida occulta/aperta and/or
2 1 ----------- 1 ---------- ----------- 4
hydrocephalus 1* \f ----------- ----------- ---------- 1" 3
Microcephaly ----------- r ---------- - ----------- ---------- 1 2
Others F i " 2' ----------- r 1J 12
Abbreviations as in Table 3,
° One case with congenital heart defect and microcephaly. 
b One case each: hypospadia and nail aplasia; hypospadia and umbilical hernia. 
c One case with hydronephrose and clubfeet. 
d One case with spina bifida aperta and clubfeet.
One case with meningocele and hydrocephalus.
/ One case with hydrocephalus. 
s One case with syndactyly of toes digiti II/IIL 
h One case with craniofacial dysostosis.
' One case each: unilateral lung aplasia; psychomotor retardation, seizures and strabismus.
J One case each: ptosis; IgG deficiency, epilepsy, and heart murmur; thymus aplasia, IgA deficiency, and IgG subclass I deficiency; trigonocephaly; 
MCA; absent tear ducts; double right ureter.
Epilepsia, Vol. 38, No. 9, 1997
AED USE AND MCA 989
Furthermore, in the Magdeburg group, no pregnancies 
had to be excluded because of stillbirth or neonatal death 
during the study period.
Centers differed with respect to medication prescrip­
tion and risks of MCA. Differences in risk of M CA may 
be explained in part by differences among centers in 
diagnostic procedures used. Because such differences 
may confound the analysis, we adjusted for study center 
in the pooled analysis and studied the association be­
tween AEDs and MCA (according to the standardized 
criteria) also within each study center. A higher risk of 
MCA for children exposed to VP A was detected consis­
tently in all centers that studied VPA, although the risk 
was not significant in the individual centers, most likely 
due to the small number of pregnancies exposed. If the 
association would be due to bias, this must have occurred 
similarly in all studies, which is plausible only in the case 
of confounding by indication. Confounding by indication 
implies that certain types of epilepsy that directly in­
crease the risk of MCA, may require treatment with cer­
tain AEDs, leading to a spurious association between the 
AEDs and the risk of MCA. Indeed, there was evidence 
of a relation between the type of epilepsy and the pre­
scription of AEDs in the present study. Patients with 
generalized epilepsy more often were prescribed VPA, 
ESM, PB, or PRM monotherapy and the combinations of 
VPA and PB, PRM, and CBZ or VPA and ESM. Patients 
with partial epilepsy more often received CBZ mono­
therapy or the combinations of CBZ and PHT, CBZ and 
VPA, 01* CBZ and clonazepam. Although it is difficult to 
exclude confounding by indication in an observational 
study, we noted no significant evidence of an association 
between any type of epilepsy and MCA, suggesting that 
epilepsy type is not likely to explain our results. Finally, 
bias may be related to the fact that multiple pregnancies 
in a woman were included. We therefore performed an 
analysis in which only the first pregnancy of a woman 
ascertained in the study was included. This did not 
change any of our conclusions.
VPA has previously been reported to pose an in­
creased risk of MCA. About 10 years after the introduc­
tion of VPA, the possibility of teratogenic effects became 
evident. An association with neural tube defect was ob­
served in mice (35,36). Subsequently, reports o f children 
with neural tube defects after prenatal exposure to VPA 
were published (33,37-41). A risk of 1-2% was esti­
mated on the basis of retrospective studies (33,38,42) 
and several small prospective cohort studies (41). The 
prospective study of Omtzigt et al. (23) suggested a risk 
as high as 6%. In the pooled analysis, the risk of neural 
tube defects in offspring of women treated with VPA 
was 3.8%. Our results, as well as those of animal experi­
ments (43), suggest that VPA dose is important with 
regai'd to the degree of risk of neural tube defects. An 
association between hypospadias and VPA has also been
suggested (11,33,44). The current study is inconclusive 
with regard to this finding (n =  1). The risk of neural 
tube defects for offspring exposed to CBZ was 1.0%, 
very similar to the 0.5-1%  risk reported earlier (10).
Our reanalysis of data from five prospective studies 
showed that VPA is consistently associated with an in­
creased risk of M CA in offspring exposed in utero to 
VPA. An important advantage of the present study is that 
we were able to reanalyze data of prospective European 
studies using uniform criteria for the diagnosis of MCA 
and to determine a dose-response relationship between 
the occurrence o f these MCA and the use of AEDs. For 
CBZ, we found no evidence of a dose-response relation­
ship, whereas risk remained NS for PB. Our study shows 
that in particular the offspring o f women receiving 
52=1,000 mg/day VPA appear to be at increased risk. 
Based on the risk estimates, physicians may choose not 
to use VPA monotherapy during pregnancy if satisfac­
tory seizure control can be achieved with other AEDs; if 
other AEDs cannot be substituted for VPA, use of daily 
dosages <1,000 mg/day VPA is recommended whenever 
results in effective seizure control. Although we pooled 
the data of five studies, the number of women exposed to 
a particular AED regimen, especially AED combina­
tions, remains small for a substantial number of AEDs, 
which results in risk estimates that are not stable. Despite 
the standardized case definition and gain of statistical 
power obtained in our reanalysis, the interpretation of 
our findings is still limited because of the differences in 
prescribing practices and case ascertainment among cen­
ters. Therefore, standardized single-center or multicenter 
studies with larger numbers of AED-exposed pregnan­
cies remain necessary to allow further quantification of 
the effect of the other AEDs in the etiology of MCA in 
the offspring of women with epilepsy.
We recommend performance of multicenter prospec­
tive and population-based studies of pregnancy outcome 
according to a standardized study protocol and standard­
ized study procedures, such as ascertainment procedures, 
assessment of etiological factors and outcome (including 
definition of outcome), inclusion and exclusion criteria, 
and selection of controls (if appropriate). This is espe­
cially relevant for the coming decades, in view of the 
many new AEDs currently entering the market for which 
no human clinical safety data are available with respect 
to their use during pregnancy.
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